Incident cancer risk in dipeptidyl peptidase-4 inhibitor-treated patients with type 2 diabetes mellitus

OBJECTIVE: It is known that patients with diabetes are susceptible to cancer development due to long-standing diabetic conditions. This study aimed to investigate new-onset cancer risk associated with dipeptidyl peptidase-4 (DPP-4) inhibitors as compared to metformin, the first-line antidiabetic age...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Yeo Jin, Kim, Dae Jung, Shin, Sooyoung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689554/
https://www.ncbi.nlm.nih.gov/pubmed/31496802
http://dx.doi.org/10.2147/CMAR.S215107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689554/
https://www.ncbi.nlm.nih.gov/pubmed/31496802
http://dx.doi.org/10.2147/CMAR.S215107

Ejemplares similares